Intuitive Surgical Executive Says The Company's U.S. Business, Accounting For ~60% Of Its Operations, Is Decelerating; Company's Growth Drivers Expected To Remain Broadly Consistent In 2026 YoY
– Executive comments on conference call
Stocks · News reference
Intuitive Surgical Exec Says Planned 2027 Extended-Use Instrument Program Could Provide Tailwind To Procedure Growth As Investors Weigh Slowing U.S. Growth; Bariatrics Is Just Over 2% Of Global da Vinci Procedures, With Its Incremental Impact Moderating Over Time
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Intuitive Surgical Published Systematic Review And Meta-Analysis In Peer-Reviewed Annals Of Surgery Open.
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.